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OBJECTIVE—Using the genome-wide association approach,
we recently identiﬁed the glucokinase regulatory protein gene
(GCKR, rs780094) region as a novel quantitative trait locus for
plasma triglyceride concentration in Europeans. Here, we sought
to study the association of GCKR variants with metabolic phe-
notypes, including measures of glucose homeostasis, to evaluate
the GCKR locus in samples of non-European ancestry and to ﬁne-
map across the associated genomic interval.
RESEARCH DESIGN AND METHODS—We performed asso-
ciation studies in 12 independent cohorts comprising 45,000
individuals representing several ancestral groups (whites from
Northern and Southern Europe, whites from the U.S., African
Americans from the U.S., Hispanics of Caribbean origin, and
Chinese, Malays, and Asian Indians from Singapore). We con-
ducted genetic ﬁne-mapping across the 417-kb region of link-
age disequilibrium spanning GCKR and 16 other genes on
chromosome 2p23 by imputing untyped HapMap single nucleo-
tide polymorphisms (SNPs) and genotyping 104 SNPs across the
associated genomic interval.
RESULTS—We provide comprehensive evidence that GCKR
rs780094 is associated with opposite effects on fasting plasma
triglyceride (Pmeta  3  10
56) and glucose (Pmeta  1  10
13)
concentrations. In addition, we conﬁrmed recent reports that the
same SNP is associated with C-reactive protein (CRP) level (P 
5  10
5). Both ﬁne-mapping approaches revealed a common
missense GCKR variant (rs1260326, Pro446Leu, 34% frequency, r
2
0.93 with rs780094) as the strongest association signal in the region.
CONCLUSIONS—These ﬁndings point to a molecular mecha-
nism in humans by which higher triglycerides and CRP can be
coupled with lower plasma glucose concentrations and position
GCKR in central pathways regulating both hepatic triglyceride
and glucose metabolism. Diabetes 57:3112–3121, 2008
R
ecently, in the genome-wide association Diabe-
tes Genetics Initiative (DGI) Study for 19 traits,
including plasma lipids, we provided evidence
that the glucokinase (GCK) regulatory protein
gene (GCKR) region was a novel quantitative trait locus
associated with plasma triglyceride concentration (1). Of
all single nucleotide polymorphisms (SNPs) tested, an
intronic SNP at GCKR (rs780094) explained the greatest
proportion of interindividual variability in plasma triglyc-
erides (1).
GCKR regulates GCK, which functions as a glucose
sensor responsible for glucose phosphorylation in the ﬁrst
step of glycolysis. The discoveries that inactivating muta-
From the
1Department of Clinical Sciences, University Hospital Malmo ¨,
Clinical Research Center, Lund University, Malmo ¨, Sweden; the
2Program in
Medical and Population Genetics, Broad Institute of the Massachusetts
Institute of Technology and Harvard University, Cambridge, Massachusetts;
the
3Lipids and Atherosclerosis Research Unit, Reina Soﬁa University
Hospital, University of Cordoba, Cordoba, Spain; the
4Nutrition and Genom-
ics Laboratory, Jean Mayer-U.S. Department of Agriculture Human Nutri-
tion Research Center on Aging at Tufts University, Boston, Massachusetts;
the
5Genetic and Molecular Epidemiology Unit and CIBER Fisiopatología de
la Obesidad y Nutricio ´n, School of Medicine University of Valencia, Valen-
cia, Spain; the
6Department of Genome Sciences, University of Washington,
Seattle, Washington; the
7Lillehei Heart Institute, Department of Medicine,
University of Minnesota, Minneapolis, Minnesota; the
8Center for Statistical
Genetics, Department of Biostatistics, University of Michigan School of
Public Health, Ann Arbor, Michigan; the
9Department of Endocrinology,
Singapore General Hospital, Singapore; the
10Dietary Assessment and
Epidemiology Research Program, Jean Mayer-U.S. Department of Agricul-
ture Human Nutrition Research Center on Aging, Tufts University, Boston,
Massachusetts; the
11Department of Epidemiology, University of Alabama,
Birmingham, Alabama; the
12Department of Clinical Pharmacology, Sahlg-
renska Academy, Go ¨teborg, Sweden; the
13Department of Medicine, Hel-
sinki University Hospital, University of Helsinki, Helsinki, Finland; the
14Folkha ¨lsan Research Center, Helsinki, Finland; the
15Novartis Institutes
for BioMedical Research, Cambridge, Massachusetts; the
16Department of
Clinical Sciences, Medicine, Lund University, Malmo ¨, Sweden; the
17Depart-
ment of Molecular Medicine, National Public Health Institute, Biomedicum,
Helsinki, Finland; the
18Department of Epidemiology and Health Promotion,
National Public Health Institute, Helsinki, Finland; the
19Center for Human
Genetic Research and Department of Molecular Biology, Massachusetts
General Hospital, Boston, Massachusetts; the
20Department of Genetics,
Harvard Medical School, Boston, Massachusetts; and the
21Cardiovascular
Disease Prevention Center, Cardiology Division, Department of Medicine,
Massachusetts General Hospital, Harvard Medical School, Boston,
Massachusetts.
Corresponding author: Marju Orho-Melander, marju.orho-melander@med.
lu.se.
Received 17 April 2008 and accepted 29 July 2008.
Published ahead of print at http://diabetes.diabetesjournals.org on 4 August
2008. DOI: 10.2337/db08-0516.
© 2008 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
ORIGINAL ARTICLE
3112 DIABETES, VOL. 57, NOVEMBER 2008tions in GCK cause maturity onset diabetes of the young
type 2 (2) and activating GCK mutations lead to permanent
hyperinsulinemic hypoglycemia (3) emphasize that GCK
plays a major role in glucose metabolism. GCKR-deﬁcient
mice have reduced GCK expression but maintain nearly
normal GCK activity and show impaired glucose clearance
(4). Furthermore, adenoviral-mediated overexpression of
GCKR in mouse liver increased GCK activity and lowered
fasting blood glucose (5) and overexpression of GCK in
liver led to lowered blood glucose and increased triglyc-
eride concentrations (6,7). Thus, experimental evidence
suggests that perturbation of the GCKR pathway has
opposing effects of triglyceride and glucose metabolism.
In our original report, SNP rs780094 in GCKR was
associated with fasting triglyceride levels in two indepen-
dent samples, each of Northern European ancestry (P 
3.7  10
8 and 8.7  10
8, respectively) (1). After initial
identiﬁcation and replication of a chromosomal region
associated with a trait, key next steps include extension of
the association ﬁnding to related phenotypes, validation of
the association ﬁnding in different ethnicities, and ﬁne-
mapping to identify the putative causal variant. Recently,
our initial ﬁnding was replicated in a Danish study in
which a strong association was found between the
rs780094 T allele and elevated fasting triglyceride levels
but also lower insulin levels, better insulin sensitivity, and
a moderately decreased risk of type 2 diabetes (8). In
addition, recent genome-wide association studies identi-
ﬁed an association between the same GCKR intronic SNP
and C-reactive protein (CRP) levels (9,10).
Hereby, we sought to examine the effect of SNP
rs780094 on triglycerides and related metabolic traits,
including fasting glucose concentrations, in 12 samples
representing a range of ancestral groups and including a
large prospective study with a mean follow-up time of 23
years. In addition, we performed ﬁne-mapping in one of
these samples to identify the strongest association signal
in the region.
RESEARCH DESIGN AND METHODS
The genetic association studies were performed in 12 study samples as shown
in Table 1. For all studies, informed consent was obtained from the study
subjects, and the study protocols were approved by local ethics committees.
All study cohorts genotyped for GCKR as part of this experiment are included
in this report.
The DGI Study material consisting of 2,931 individuals from Finland and
Sweden (1,464 patients with type 2 diabetes and 1,467 nondiabetic control
subjects) was ascertained as previously described (1,11,12). DGI samples
were genotyped on the Affymetrix 500K chip (1) and were used in the present
study for the in silico ﬁne-mapping. In addition, the DGI samples were used for
the genotype ﬁne-mapping of the GCKR locus and for the analyses of
apolipoprotein B (apoB) and free fatty acids (FFAs) according to rs780094.
The Malmo ¨ Diet and Cancer Study–Cardiovascular Cohort (MDC-CC)
represents 6,103 people that were randomly selected to participate in a study
of the epidemiology of carotid artery disease from a large, community-based
prospective epidemiological cohort of 28,449 people recruited for a baseline
examination between 1991 and 1996 (13). Of the MDC-CC participants, 597 did
not provide a baseline plasma sample or did not have triglyceride data
available, leaving 5,506 individuals available for the analyses of lipid traits. Of
these, 5,023 nondiabetic individuals had data on fasting blood glucose, and
4,867 had data on fasting insulin. In MDC-CC, cardiovascular events were
ascertained through linkage of the 10-digit personal identiﬁcation number of
each Swedish citizen with three registries: the Swedish Hospital Discharge
Register, the Swedish Cause of Death Register, and the Stroke Register of
Malmo ¨. The prespeciﬁed composite end point of cardiovascular events was
deﬁned as myocardial infarction (according to codes 410 and 121 in ICD-9 and
ICD-10), ischemic stroke (according to codes 434 and 436 in ICD-9 and I63 or
I64 in ICD-10), and death from coronary heart disease (codes 412 and 414 in
ICD-9 or I22-I23 and I25 in ICD-10 in the Swedish Cause of Death Register). We
excluded cases of intracerebral or subarachnoid hemorrhage. The status of
cigarette smoking was elicited by a self-administered questionnaire and was
coded as never, former, or current. A parental or sibling history of myocardial
infarction was also elicited by a questionnaire. CRP was measured by a
high-sensitivity assay (Tina-quant CRP; Roche Diagnostics). Study partici-
pants underwent a B-mode ultrasonography of the right carotid artery.
Intima-media thickness (IMT) of the common carotid artery was measured
according to standardized protocol by a trained certiﬁed sonographer as
previously described (14,15).
In the Malmo ¨ Preventive Project (MPP), 33,346 citizens from Malmo ¨i n
southern Sweden participated in a health screening during 1974–1992 (16). Of
individuals participating in the initial screening, 4,931 had died, and 551 were
lost from follow-up. Of the eligible individuals, 25,000 were invited to a
rescreening visit during 2002–2006, which included a physical examination
and fasting blood samples for measurements of plasma glucose and lipids. Of
the invited subjects, 17,284 people participated in the rescreening, and of
these, 17,037 individuals had DNA, 16,998 individuals had fasting triglyceride
data, and 16,976 individuals had fasting glucose data available for the study.
The mean follow-up time was 23.4  4.6 years. Of the 17,037 individuals, 5,946
were also participants of the MDC-CC, bringing the number of unique
individuals in the MPP (i.e., not included in MDC-CC) to 11,091. Because of the
overlap between MDC-CC and MPP materials, all of the phenotype association
analyses in MPP included in the meta-analysis were performed in the unique
cohort of 11,091 participants, whereas the prospective analyses were per-
formed in the whole MPP cohort with DNA and available phenotypes.
Individuals on lipid-lowering medication (n  3,510) were excluded from the
triglyceride analyses, and individuals with diabetes either at baseline or
follow-up (n  3,029) were excluded from the analyses of fasting blood
glucose. For the analysis of progression to type 2 diabetes in MPP, 16,061
nondiabetic subjects, 2,063 of whom developed type 2 diabetes, were in-
cluded. Diagnosis of diabetes was conﬁrmed from patient records or based on
a fasting plasma glucose concentration 7.0 mmol/l.
During the follow-up visit, a subgroup from the MPP study participated in
more extensive metabolic studies, including a euglycemic-hyperinsulinemic
clamp combined with indirect calorimetry to measure hepatic glucose output.
All individuals underwent a physical examination, and a subgroup of 199 men
(Malmo ¨ men, MPP-MM) with impaired glucose tolerance (IGT) underwent
more extensive metabolic studies, including a new oral glucose tolerance test
(OGTT) and a euglycemic-hyperinsulinemic clamp combined with infusion of
[3-H
3]glucose to measure hepatic glucose output (17). After the follow-up
time, 66 of the 199 men with IGT at baseline had normal glucose tolerance, 52
had impaired fasting glucose and/or IGT, and 81 had type 2 diabetes. Type 2
diabetic patients were treated either with diet alone (42%) or with oral
hypoglycemic agents, which were withheld the day before the clamp.
The Nordic Diltiazem (NORDIL) Study is an intervention study in 10,881
patients with hypertension from Sweden and Norway (diastolic blood pres-
sure 100 mmHg at least twice, mean age 60  7 years) of whom 5,152
Swedish patients provided DNA and were included in the present study (18).
The study participants had been randomized to antihypertensive treatment
with either the calcium-antagonist diltiazem or -blocker/thiazide diuretic to
compare efﬁcacy of the two drug therapies to prevent cardiovascular end
points (18). Lipoprotein and lipid measurements at the baseline examination
(before the initiation of antihypertensive therapy) were studied in this report.
The Diabetes Registry sample consists of 2,777 type 2 diabetic patients
from the Skania Diabetes 2000 Registry, a local diabetes registry in southern
Sweden (19). The majority of registered patients came from the city of Malmo ¨
in southern Sweden. Type 2 diabetes was classiﬁed according to 1997 World
Health Organization (WHO) criteria (20).
The Botnia-Prevalence, Prediction, and Prevention of Diabetes (Botnia-
PPP) Study is a population-based study from the Botnia region of western
Finland. The current study was initiated in 2004 in a population comprising
135,000 individuals. Using a population registry, a random sample of
subjects aged 18–75 years was selected: In age-groups 18–29 and 60–74 years,
1 of 10 individuals was randomly selected; and in age-group 30–59 years, 1 of
15 individuals was randomly selected. Altogether, 6,075 individuals were
invited to participate in the study, and 3,621 took part. Of these individuals,
3,495 have data and DNA available for the current study.
The FINRISK97 study is a population-based cross-sectional survey
which consists of 8,191 people aged 25–74 years from ﬁve geographical
areas of Finland (the Helsinki, southwestern Finland, North Karelia, Oulu,
and Kuopio regions) (21). The study followed the protocol of the WHO
Multinational Monitoring of Trends and Determinants in Cardiovascular
Disease (MONICA) Project, an international study conducted under the
auspices of the WHO.
The Valencia study population comprised 1,608 individuals randomly
selected from the Valencia region on the eastern Mediterranean coast of Spain
and examined between 1999 and 2003 (22). This sample comprised randomly
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register, and subjects randomly selected from the general population.
The Dallas Heart Study is a multiethnic, probability-based sample of Dallas
County, weighted such that 50% of the study population was black (23).
Ethnicity was self-reported and consisted of non-Hispanic blacks, non-
Hispanic whites, and Hispanics. The study population included 3,469 individ-
uals from one of these three ethnic groups with fasting venous blood samples.
The Genetics of Lipid-Lowering Drugs and Diet Network (GOLDN) Study
sample consists of 1,062 individuals and is part of the Program for Genetic
Interactions Network (24). The majority of participants in the GOLDN Study
were re-recruited from three-generational pedigrees from two National Heart,
Lung, and Blood Institute (NHLBI) Family Heart Study (FHS) ﬁeld centers
(Minneapolis, MN, and Salt Lake City, UT) (24). The NHLBI FHS is a
multicenter, population-based study of genetic and environmental determi-
nants of cardiovascular disease (CVD) and associated risk factors. Nearly all
subjects were of European ancestry.
The longitudinal Boston Puerto Rican Health Study includes 837 Puerto
Rican (Hispanics of Caribbean origin) men and women aged 45–75 years in the
greater Boston area (25,26). As one of eight nationally funded National
Institutes of Health (NIH) Centers on Population Health and Health Dispari-
ties, the study is investigating health disparities in the Puerto Rican popula-
tion. Participants were recruited from the Boston area through door-to-door
enumeration, following a sampling scheme based on identiﬁcation of the 2000
U.S. Census blocks containing Hispanics, and in partnership with community
organizations.
The Singaporean National Health Survey 98 (Singaporean NHS-98) study
was an initiative to determine the risk factors for the major noncommunicable
diseases in Singapore (27,28). A total of 3,973 subjects who participated in the
Singaporean NHS-98 and had the data needed for the current study were
included in this study. In brief, 11,200 individuals from addresses representing
the house-type (a proxy for socioeconomic status) distribution of the entire
Singapore housing population were selected from the National Database on
Dwellings. From these individuals, a random sample was selected by dispro-
portionate stratiﬁed and systematic sampling. The Malays and Indians were
oversampled to ensure that prevalence estimates for these minority groups
were reliable.
Lipid and glucose phenotypes. Plasma total cholesterol, HDL cholesterol,
and triglycerides in each study were measured using standard enzymatic
methods from fasting blood samples, with the exception of FINRISK97, in
which the lipid measurements were performed from blood samples collected
in a “semifasting” state; i.e., the participants were instructed to fast for4ha n d
to avoid fatty meals earlier during the day. ApoB in the DGI was measured
using an immunochemical assay (Orion Diagnostica, Espoo, Finland), and
FFA was measured by an enzymatic colorimetric ACS-ACOD-MEHA method
(Wako Chemicals, Neus, Germany).
Fasting blood or plasma glucose was measured by glucose oxidase
methods as previously described (1,16–18, 22–27), and blood glucose was
converted to plasma glucose using a correction factor of 1.13. Fasting serum
insulin was measured using radioimmunoassay in DGI, MDC-CC, MPP-MM,
GOLDN, and Singaporean NHS-98 samples (1,11–13,21,24,25). Homeostasis
model assessment (HOMA) insulin resistance index was calculated using the
following formula: fasting plasma glucose  fasting insulin/22.5. The insuli-
nogenic index was calculated as [(insulin 30  fasting insulin)/(glucose 30 
fasting glucose)].
Genotyping. Genotyping was performed either by matrix-assisted laser
desorption ionization-time of ﬂight mass spectrometry on the Sequenom
MassARRAY platform (San Diego, CA) or by allelic discrimination method on
the ABI 7900 instrument (Applied Biosystems, Foster City, CA). The studied
SNPs were in Hardy-Weinberg equilibrium in all studied populations (P 
0.01) except rs780094 in the Singaporean Chinese population (P  0.000063).
Because of deviation from Hardy-Weinberg equilibrium, a random sample of
12% of the Chinese samples was reanalyzed in a separate assay, and the
genotyping error rate was 0.3%.
Genotype ﬁne-mapping. GCKR rs780094 lies in a large region of linkage
disequilibrium on chromosome 2. We deﬁned the associated interval to be
417 kb based on linkage disequilibrium between the index SNP (rs780094)
and SNPs upstream and downstream of the index SNP. rs1049817 was furthest
upstream with an r
2 0.25 with the index SNP, and rs13023194 was the
furthest downstream with an r
2 0.25 with the index SNP. The interval
between rs1049817 and rs13023194 spans 416,543 bases (National Center for
Biotechnology Information human genome sequence Build 35). In this inter-
val, there are 17 annotated genes: MPV17, GTF3C2, EIF2B4, SNX17, ZNF513,
PPM1G, NRBP1, KRTCAP3, IFT172, FNDC4, GCKR, C2orf16, ZNF512,
CCDC121, XAB1, SUPT7L, and SLC4A1AP. To ﬁne-map the association signal
across this interval, we selected 120 SNPs for genotyping based on the
following criteria: 1) tag SNPs (n  33) that captured all common SNPs
(minor allele frequency 0.05) across the 417 kb at an r
2 0.8; 2) all coding
SNPs (n  83) present in HapMap CEU for these genes; and 3) a set of SNPs
predicted to be microRNA binding sites (n  4). Of these 120 SNPs, 104 were
successfully designed for genotyping assays and were genotyped in the DGI
sample.
In silico ﬁne-mapping. We also conducted ﬁne-mapping using a second
approach: imputation of untyped SNPs. We imputed untyped SNPs across the
region using a recently developed Markov Chain Haplotyping algorithm
(MACH 1.0) (29). This method predicts genotypes for untyped SNPs in a given
study using two inputs: genotypes at typed SNPs in the study sample and the
entire set of genotypes in HapMap (www.hapmap.org) for a given reference
sample. Here, the inputs were the following: genotypes from the Affymetrix
500K array in the DGI study and 2.2 million SNPs in the HapMap CEU
samples (a reference sample of European ancestry).
Expression studies. To evaluate whether the transcript level of GCKR or
GCK varied by genotype, we studied 101 human liver samples with both
measured transcript levels and genotypes. Transcript levels for 60 samples
were assessed by the Human Ref8 v.2 Illumina chip, and genotypes were
measured by the Illumina 550K array (30). For 41 additional samples, GCKR
and GCK transcript levels were measured in human liver tissue obtained from
the University of Minnesota Tissue Procurement Center (Minneapolis, MN)
following institutional review board guidelines. DNA was extracted using a
Qiagen extraction protocol accorded to the manufacturer’s directions. Sam-
ples were genotyped by primer extension with detection by matrix-assisted
TABLE 1
Clinical characteristics of the study cohorts
Finland
and
Sweden Sweden Finland
DGI
(ref. 1)
MDC-CC
(ref. 13)
MPP
(ref. 16)
NORDIL
(ref. 18)
Skania
Diabetes
2000
Registry
(ref. 19) Botnia-PPP FINRISK97
n 2,930 5,506 17,037 5,152 2,777 3,495 8,191
n (men/women) 1,448/1,482 2,282/3,224 10,927/6,110 2,567/2,585 1,583/1,075 1,663/1,841 4,082/4,109
Age (years) 62  11 58  64 6  76 0  76 3  11 49  16 48  13
BMI (kg/m
2) 28  42 6  42 4  32 8  43 0  52 6  42 7  5
Triglycerides (mg/dl) 144  101 122  71 117  71 159  108 231  275 116  71 133  92
HDL (mg/dl) 49  15 53  14 — 53  21 44  13 — 54  14
LDL (mg/dl) 145  51 161  38 — 160  43 137  40 — 134  36
fB-glucose (mg/dl) 121  49 93  25 88  13 96  28 189  69 84  15 —
HOMA (mmol  mU) 1.7  1.4 2.0  2.7 — — — — —
Type 2 diabetes (%) 49.9 8.4 0.0 8.7 100.0 3.8 5.4
Continued on facing page
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3114 DIABETES, VOL. 57, NOVEMBER 2008laser desorption ionization-time of ﬂight mass spectroscopy using a Sequenom
platform. RNA was extracted using the Qiagen RNeasy mini kit on pulverized
tissue according to the manufacturer’s protocols (Qiagen). RNA was reverse
transcribed to cDNA using the Superscript III ﬁrst-strand synthesis from
Invitrogen. RT-PCR was performed on an ABI 7900 using ABI TaqMan primer
probe sets (HS01564551_G1, GCK; and HS01100274_M1, GCKR) and normal-
ized to cyclophilin. Data are expressed as Ct (cycle threshold) values.
Statistical analyses. SNP-phenotype association analyses were performed
by multivariate linear regression using an additive genetic model. Because of
deviation from normal distribution, fasting triglyceride, blood glucose, and
CRP concentrations, and carotid IMT measurements were log transformed
before analyses. For each participant, residual values were created for
log-triglycerides, HDL cholesterol, and LDL cholesterol after adjustment for
age, sex, and diabetes status. Residuals were created for BMI after adjustment
for age and sex. For analyses of lipid traits, individuals on lipid-lowering
medication were excluded (except in NORDIL and Diabetes Registry, where
this information was not available). Log-fasting glucose, HOMA insulin
resistance index, and insulinogenic index were studied only in nondiabetic
individuals, and residuals were created after adjustment for age and sex. To
limit the undue inﬂuence of outliers in the regression analysis, for each trait
we excluded the bottom and top 0.5% of the trait-level distribution in each
study sample. We tested the null hypothesis that the trait residuals do not
differ by the analyzed genotypes.
To summarize the statistical evidence across the multiple cohorts, we
conducted a ﬁxed-effects variance-weighted meta-analysis. We computed a
weighted average of the -coefﬁcient estimates and SEs (from the linear
regression models) using the inverse of the variance in each cohort as weights.
Heterogeneity between the studies was tested using the Cochran test.
One-way ANOVA was used to compare expression levels of GCK and GCKR
in the human liver samples according to genotype. Survival analyses were
performed using Cox regression analysis with either age and sex or age, sex,
LDL cholesterol, HDL cholesterol, triglycerides, BMI, systolic blood pressure
(sBP), diastolic blood pressure (dBP), smoking, family history of myocardial
infarction, lipid-lowering medication, antihypertensive medication, and log-
CRP as independent predictors.
Analysis of association between log-carotid IMT and GCKR was performed
by linear regression analysis in individuals without prevalent myocardial
infarction or type 2 diabetes after adjustment for age and sex. Because our
sample included a modest number of CVD events (321 incident case subjects
and 4,781 event-free control subjects), we assessed power to detect an
association between GCKR SNP genotype and CVD. We approximated haz-
ards ratios using case-control design for discrete traits (31). At 5% signiﬁcance
level, we had a power of 0.58 for a SNP genotype with an odds ratio (OR) of
1.2 per risk allele (that is, OR 1.00, 1.20, and 1.44 for carriers of 0, 1, and 2 risk
alleles, respectively), power 0.88 for an OR of 1.30, and power 0.98 for an OR
of 1.4 per risk allele, assuming a risk allele frequency of 34% (the Leu allele of
SNP rs1260326 has an allele frequency of 34%). For the association of
Pro446Leu with carotid IMT (n  4,859 individuals analyzed), at 5% signiﬁ-
cance level, we had a power of 0.88 to detect an association for a SNP
genotype that explained 0.2% of the variance in carotid IMT.
In the MPP prospective study, the ORs for risk of developing type 2
diabetes were calculated using logistic regression analyses adjusted for age at
inclusion and time to last follow-up, BMI, and sex. Differences in change of
fasting triglyceride by genotype during the follow-up time were tested by
linear regression analysis adjusted for age at inclusion, sex, time to last
follow-up, and diabetes status. After excluding individuals with diabetes at
baseline and on follow-up, differences in change of fasting glucose were tested
using linear regression analyses with adjustment for age at inclusion, sex, and
time to last follow-up.
All statistical analyses were conducted using either SPSS version 14.0 or
PLINK (32). All nominal P values of 	0.05 were considered signiﬁcant. All
reported P values are two sided.
RESULTS
Association with plasma triglyceride concentrations.
The initial association of rs780094 with triglyceride con-
centrations was studied in each of 12 study samples,
representing a range of ancestral groups (Table 2). In all
but one sample, the T allele was associated with higher
triglycerides (Table 2; P for association ranging from 0.29
to 6  10
10); for example, in the MDC-CC, each copy of
the T allele was associated with 5.5 mg/dl higher triglyc-
erides. Across the studies, SNP rs780094 explained be-
tween 0.1 and 1.2% of triglyceride variance (after
accounting for age, sex, and diabetes status).
Combining the data from the studied 46,549 individuals
provided robust evidence for association between the
minor T allele at rs780094 and higher triglyceride levels
(meta-analysis P  3  10
56; Table 2). The minor T-allele
frequency varied from 16.1% in U.S. blacks to 47.6% in the
Spanish from Valencia, and the effect size per T allele
ranged from 0.6 mg/dl in Dallas Heart Study Hispanics to
6.2 mg/dl in the MPP (Table 2). Mean effect size was 4.2
mg/dl, and we did not observe signiﬁcant heterogeneity
between the studies (P  0.15). We found that the T allele
was associated with higher triglycerides in population-
based samples and in cohorts of patients with diabetes and
hypertension. Furthermore, the T allele was associated
with higher triglycerides regardless of the mean triglycer-
TABLE 1
Continued
Spain U.S. Singapore
Valencia
Dallas
Heart
Study
GOLDN
(ref. 24)
BPRHS
(refs. 25,26)
NHS-98
(refs. 27, 28)
Blacks Hispanics Whites Chinese Malays
Asian
Indians
1,608 1,825 601 1,043 1,062 837 2,691 734 548
760/848 770/1,055 251/350 500/543 506/556 225/612 1,227/1,464 353/381 262/286
42  14 45  10 40  94 5  10 49  16 58  73 8  12 39  13 41  12
26  53 2  83 1  72 9  72 8  63 2  82 3  42 6  52 5  5
112  66 107  95 151  130 139  107 135  85 159  99 120  72 143  87 145  83
51  11 52  15 46  11 48  15 47  13 45  12 55  14 50  13 44  12
131  36 105  37 107  33 108  34 131  34 122  31 108  35 150  42 143  40
96  24 105  49 106  43 98  34 101  18 124  54 101  24 109  39 111  38
— — — — 3.6  2.6 — 1.8  1.3 2.4  2.2 2.8  2.5
3.9 14.2 12.0 6.6 7.6 35.7 2.2 4.5 8.4
Data are means  SD (continuous measures). To convert the values to millimoles per liter, multiply triglycerides by 0.01129, HDL and LDL
by 0.02586, and fasting blood glucose (fB-glucose) by 0.0556. BPRHS, Boston Puerto Rican Health Study.
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DIABETES, VOL. 57, NOVEMBER 2008 3115ide level in the sample (e.g., the mean triglyceride concen-
tration is considerably lower in a population-based
sample, such as MDC-CC [at 122 mg/dl] compared with the
Diabetes Registry cohort [at 231 mg/dl] comprising en-
tirely individuals with type 2 diabetes).
Association with plasma triglyceride–related meta-
bolic traits. We next explored the relationship between
SNP rs780094 and related metabolic traits, including
plasma LDL cholesterol, HDL cholesterol, apolipoprotein
concentrations, FFA concentrations, and BMI. SNP
rs780094 was not associated with LDL cholesterol or HDL
cholesterol in any of the samples (supplementary Table 1,
which is available in an online appendix at http://dx.doi.
org/10.2337/db08-0516). As expected, given the correlation
between triglyceride and apoB concentration (r  0.42
[P 	 0.0001] and 0.57 [P 	 0.0001] in DGI and FINRISK97,
respectively), rs780094 was associated with apoB concen-
tration in a meta-analysis of the DGI and FINRISK97
cohorts (P  7.5  10
5), with the T-allele carriers having
the highest apoB concentration. Fasting FFA and triglyc-
eride concentrations are weakly correlated (r  0.25 and
0.20 in DGI and MPP-MM, respectively), and we did not
observe any association between rs780094 and fasting FFA
(P  0.39 and 0.90 in DGI and MPP-MM cohorts, respec-
tively) or suppression of FFA levels at2hi na nOGTT (P 
0.70 and 0.98 in DGI and MPP-MM cohorts, respectively).
GCKR rs780094 was nominally associated with BMI in the
Singaporean NHS-98 study (P  0.04) but not in any of the
other samples (supplementary Table 2).
Because two genome-wide association studies recently
reported association between CRP levels and rs780094 and
rs1260326 (9,10), we tested for association between GCKR
rs1260326 and rs780094 and CRP in MDC-CC. Both SNPs
were strongly associated with CRP levels with the T-allele
carriers having signiﬁcantly higher levels (CC 2.5  4.7, CT
2.6  4.2, and TT 2.9  4.3 mg/l, P  4.5  10
5 in linear
regression analysis of rs1260326 adjusted for age and sex).
Association with measures of glucose metabolism. We
studied the association of SNP rs780094 with fasting
glucose concentrations in 33,995 nondiabetic individuals
and HOMA estimates of insulin resistance in 11,084 non-
diabetic individuals. Despite the fact that the T allele was
consistently associated with higher triglycerides, T-allele
carriers had signiﬁcantly lower fasting plasma glucose
levels in six of the studied populations, and a similar trend
was observed in the other populations (Table 3, Pmeta 
1  10
13); for example, in the MDC-CC, each copy of the
T allele was associated with 0.5 mg/dl lower fasting
blood glucose. In addition, T-allele carriers were more
insulin sensitive as estimated by the HOMA insulin resis-
tance index (Pmeta  5.0  10
5). In DGI and Botnia PPP
cohorts, we could calculate the insulinogenic index during
an OGTT in 999 and 3,184 nondiabetic individuals, respec-
tively. Insulin secretion capacity calculated as the insuli-
nogenic index did not differ signiﬁcantly between the
different GCKR genotype carriers (P  0.72 and 0.27,
respectively).
Encouraged by these results for intermediate traits, we
also tested association of rs780094 with type 2 diabetes in
our Nordic cohorts with similar minor allele frequency of
the SNP (DGI, MDC-CC, NORDIL, Diabetes Registry, and
FINRISK97). Of 24,034 individuals, 5,578 had type 2 diabe-
TABLE 2
Triglyceride concentrations according to genotype at GCKR rs780094* in 12 studies comprising 46,549 individuals
Country Study CC (mg/dl) CT (mg/dl) TT (mg/dl)
Minor
allele
frequency Z score P value
Finland and
Sweden DGI* 136  89 (1,142) 144  103 (1,194) 164  114 (300) 0.34 5.76 3.7  10
8
Sweden MDC-CC* 117  70 (2,207) 123  71 (2,457) 128  74 (639) 0.35 5.45 1.7  10
7
Sweden MPP 107  70 (4,059) 113  77 (4,616) 117  72 (1,425) 0.37 6.17 1.3  10
9
Sweden NORDIL 151  78 (2,223) 157  79 (2,220) 172  87 (572) 0.34 6.14 7.4  10
9
Sweden Skania Diabetes
2000 Registry
205  148 (1,076) 224  97 (1,069) 253  104 (259) 0.33 4.87 1.8  10
6
Finland Botnia-PPP 106  58 (1,273) 115  69 (1,429) 125  69 (409) 0.36 5.62 4.8  10
8
Finland FINRISK 128  86 (3,009) 130  89 (3,398) 142  105 (931) 0.36 5.00 8.0  10
7
Spain Valencia 108  66 (446) 112  64 (792) 118  71 (370) 0.48 2.26 0.02
U.S. Dallas Heart Study
blacks
103  90 (1,163) 108  78 (444) 110  59 (44) 0.16 2.53 0.01
U.S. Dallas Heart Study
Hispanics
149  138 (244) 151  124 (263) 161  155 (58) 0.34 0.56 0.29
U.S. Dallas Heart Study
whites
131  115 (342) 135  97 (455) 164  124 (145) 0.40 4.04 4.4  10
5
U.S. GOLDN 109  75 (378) 143  90 (538) 133  87 (146) 0.39 2.24 0.03
U.S. BPRHS 153  104 (423) 165  92 (330) 174  118 (84) 0.30 2.96 0.003
Singapore Singapore NHS-98
Chinese
112  64 (842) 120  71 (1233) 131  82 (616) 0.46 5.41 3.0  10
5
Singapore Singapore NHS-98
Malays
132  75 (268) 150  91 (332) 153  97 (134) 0.41 0.02
Singapore Singapore NHS-98
Asian Indians
140  79 (332) 151  89 (188) 163  109 (28) 0.22 0.08
Total n  46,549 19,427 20,958 6,164 Meta-analysis P value 3  10
56
Data means  SD (n) (continuous raw measures). Association analyses were conducted with an outcome variable of residual log- triglyceride
concentration after adjustment for age, sex, and diabetes status. For ease of interpretation, unadjusted triglyceride concentrations are
presented in the table. To convert the values to millimoles per liter, multiply triglycerides by 0.01129. All P values are two sided. *DGI and
MDC-CC results have been reported in ref. 1. BPRHS, Boston Puerto Rican Health Study.
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DIABETES, VOL. 57, NOVEMBER 2008 3117tes, and the frequency of the rs780094 T-allele was 35.2%
among nondiabetic individuals compared with 33.4% in
type 2 diabetic patients (OR 0.93 [95% CI 0.88–0.97], P 
0.0006). Of the nondiabetic individuals, 2.3% were homozy-
gous for the T allele compared with 10.9% of type 2
diabetic patients, and the TT genotype was associated
with a protection from type 2 diabetes when compared
with CC-genotype carriers (OR 0.84 [0.76–0.93], P 
0.0008).
We next evaluated whether the rs780094 genotype was
associated with hepatic glucose output in 125 men who
had undergone a hyperinsulinemic-euglycemic clamp with
infusion of [3-H
3]glucose and assessment of basal and
clamp hepatic glucose production. GCKR rs780094 T-allele
carriers did not have a signiﬁcantly lower basal rate of
hepatic glucose production (CC 2.26  0.27, CT 2.18 
0.20, and TT 2.16  0.09 mg  kg
1  min
1, P  0.10), but
their hepatic glucose output during the hyperinsulinemic
state was slightly lower compared with that of C-allele
carriers (CC 0.26  0.59, CT 0.20  0.40, and TT 0.09 
0.22 mg  kg
1  min
1, P  0.01).
Fine-mapping of the GCKR locus. We ﬁne-mapped the
GCKR region with two different approaches, by genotyp-
ing tag and coding SNPs across the region and by imputing
untyped SNPs (or so-called in silico ﬁne-mapping) (Fig. 1).
We genotyped 104 SNPs across the 417-kb region and
studied the association of these SNPs with triglyceride
concentrations (supplementary Table 3). A common
GCKR coding SNP rs1260326 (Pro446Leu) gave the stron-
gest signal for association with triglycerides (P  9.4 
10
10).
Fine-mapping by imputation also revealed that GCKR
coding SNP rs1260326 (Pro446Leu) gave the strongest
signal for triglyceride concentrations (P  1.5  10
9)i n
the associated interval on chromosome 2p23. In HapMap
CEU, GCKR coding SNP rs1260326 shows strong linkage
disequilibrium to the intronic SNP rs780094 (r
2  0.93).
We performed regression analysis, including both
rs1260326 and rs780094 as predictors of triglyceride levels
in MDC-CC, but because of the strong correlation be-
tween the SNPs, none of the two were signiﬁcant in this
analysis (P  0.18 and 0.80 for rs1260326 and rs780094,
respectively).
Figure 1 summarizes the results of both ﬁne-mapping
approaches. Both the genotyping and the in silico ﬁne-
mapping methods indicated the Pro446Leu as the variant
with strongest association with triglyceride levels. To
evaluate the ﬁdelity of the MACH imputation algorithm
(24), we compared the genotypes generated by Sequenom
genotyping for 57 SNPs with that predicted by imputation.
The genotype consensus rate was 95.7%.
Longitudinal changes in fasting triglyceride and glu-
cose stratiﬁed by GCKR Pro446Leu genotype. In the
MPP cohort, the Pro446Leu was strongly associated
with higher triglycerides and lower fasting blood glu-
cose both at baseline (P  6  10
22 and 0.0005,
respectively) and after the mean follow-up period of
23.4 years (P  3  10
29 and 0.004, respectively) (Fig.
2). In addition, the triglyceride levels of the Leu446
carriers increased more over time compared with those
of homozygous Pro446 carriers (P  8  10
5), whereas
change in fasting glucose over time did not differ by
genotype status (Fig. 2).
In the MPP study, among 17,037 individuals free of type
2 diabetes at baseline, 2,063 (12.1%) individuals developed
type 2 diabetes during the follow-up period. Carriage of
the Leu allele trended to protect from development of type
2 diabetes (OR 0.96 [95% CI 0.91–1.02], P  0.27).
Association of GCKR variation with CVD and carotid
IMT. In MDC-CC, 321 individuals experienced the ﬁrst
CVD end point during the mean follow-up time of 10.5 
1.8 years. Neither rs780094 nor rs1260326 predicted CVD
(P  0.85 and 0.45, respectively). The results were similar
when age, sex, LDL cholesterol, HDL cholesterol, triglyc-
erides, BMI, sBP, dBP, smoking, family history of myocar-
dial infarction, lipid-lowering medication, antihypertensive
medication, and CRP were included as covariates. GCKR
variants were also not associated with carotid IMT in
MDC-CC. No association was detected between GCKR
variants and common carotid artery IMT (P  0.94 and
0.63 for rs780094 and rs1260326, respectively).
Hepatic expression of GCK and GCKR according to
GCKR genotypes. We next examined whether rs780094
or Pro446Leu was associated with transcript levels of
GCKR and/or GCK in human liver. In a modest number of
liver samples (n  60), neither rs780094 nor Pro446Leu
genotype was associated with transcript levels of GCK or
GCKR (supplementary Table 4).
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FIG. 1. In silico and genotype ﬁne-mapping of the GCKR locus. To deﬁne the strongest signal for the association on chromosome 2p23 for
triglycerides, a region spanning 417 kb and containing 17 annotated genes was ﬁne-mapped by two different approaches, imputation of untyped
SNPs (29) (or so-called in silico ﬁne-mapping) (A) and genotyping tagging SNPs across the region (B). Both in silico and genotype ﬁne-mapping
methods indicated the Pro446Leu as the variant with the strongest association with triglyceride levels. The genotype consensus rate between the
imputed genotypes and genotyped genotypes was 95.7%.
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In line with the opposite effects of GCKR-pathway manip-
ulation on glucose and triglyceride concentrations in ro-
dent models and a recent association study in Danes (8),
our study provides compelling evidence that common
DNA sequence variants in GCKR are associated with
opposite effects on fasting triglyceride and glucose con-
centrations in humans and modest protection from type 2
diabetes. Both imputation and genotype ﬁne-mapping of
the GCKR locus yielded a nonsynonymous coding SNP
(Pro446Leu) as the strongest association signal, suggest-
ing the hypothesis that this nonsynonymous coding SNP is
the causal variant for the observed associations. We also
provide evidence that the Leu446 allele carriers increase
their triglyceride levels more over time compared with
noncarriers. In addition, our data suggest that, at least
within regions of high linkage disequilibrium, genotypes
predicted by imputation are highly accurate and may
provide a good starting point for genotype ﬁne-mapping.
The exact mechanism for the effect of the GCKR variant
on blood glucose, triglycerides, and CRP remains to be
deﬁned. A potential explanation is the opposite and over-
riding effects of increased glucose utilization and glyco-
lytic ﬂux on liver glucose and lipid metabolism. With
increased glucose utilization and glycolytic ﬂux, PEPCK
and glucose-6-phosphatase are downregulated, whereas
GCK, phosphofructokinase, and fatty acid synthase are
upregulated. These changes increase glycogen synthesis
and malonyl CoA concentration and direct fatty-acyl-CoA
into de novo lipogenesis and VLDL triglyceride production
(33). However, the consequence of in vivo glucose metab-
olism is enhanced suppression of hepatic glucose output
(33). Our observation that the GCKR variant T allele
associates with higher triglycerides, lower fasting glucose,
and lower hepatic glucose output during a euglyemic-
hyperinsulinemic clamp agrees with this hypothesis. Fi-
nally, the T-allele carriers had insulin secretion capacity
similar to that of noncarriers. Thus, the association is
similar to that of GCK-30G/A, which affects the glucose
levels needed to induce insulin secretion.
Our human studies propose the hypothesis that GCKR
Pro446Leu may mimic the consequences of GCK overex-
pression in rodent models with upregulaton of glucose
utilization and VLDL-triglyceride synthesis and downregu-
lation of gluconeogenesis. The Pro446Leu variant has been
introduced into rat cDNA but was not found to affect the
functional properties of the rat protein when prepared by
overexpression in Escherichia coli (34). Unfortunately,
the human protein could not be produced using that
expression system (32). Although human and rat GCKR
share 88% identity, the human protein is importantly
different from rat GCKR: human GCKR is a more potent
inhibitor of GCK than rat GCKR in the absence of fructose-
6-phosphate, and human GCKR has higher afﬁnity for
fructose-6-phosphate (35). Thus, the potential impact of
the amino acid difference on overall structure and function
of human GCKR remains to be deﬁned.
There are conﬂicting data on the association between
circulating triglyceride concentrations and risk of CVD
(36,37). Our data combined with data for other common
variants suggest a potential explanation for the varying
risk associated with high triglycerides. DNA sequence
variants in some genes (e.g., APOB) have been associated
with both increased triglycerides and markers of increased
atherosclerosis risk, such as elevated LDL cholesterol
(38). Similarly, common genetic variations in both lipopro-
tein lipase (LPL) and apoA5 (APOA5) genes (rs328 and rs
3133506, respectively) are associated with both increased
triglycerides and markers of increased atherosclerosis
risk, such as decreased HDL cholesterol (39,40). However,
at GCKR Pro446Leu, the variant allele is associated with
higher triglycerides and higher CRP levels but also with a
favorable metabolic marker, namely decreased glucose.
Our ﬁnding of no association between the GCKR variant
and CVD events or carotid IMT is thus not surprising but
instead proposes that the risk of CVD associated with
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FIG. 2. Fasting triglycerides and blood glucose levels in MPP participants before and after a mean follow-up time of 23.4 years according to GCKR
Pro446Leu. In a large prospective study, the Pro446Leu was strongly associated with higher triglycerides and lower fasting blood glucose both
at baseline and after the follow-up. In addition, among 12,528 individuals not on lipid-lowering medication, fasting triglyceride levels increased
more during the follow-up time among Leu446 allele carriers compared with homozygous Pro446 carriers (P  8  10
5), whereas the change in
fasting blood glucose during the follow-up time was not signiﬁcant among 12,964 individuals without diabetes either at baseline or at follow-up.
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of genetic variants in different genes contributing to an
increased triglyceride concentration. However, given the
limited number of CVD events in our study, this result
needs further conﬁrmation in other studies.
We provide convincing evidence that common variation
in GCKR is associated with opposite effects on fasting
plasma triglyceride and glucose concentrations in multiple
human populations and demonstrate that the strongest
association signal resides at coding SNP rs1260326
(Pro446Leu) in GCKR. Taken together, the data position
GCKR in central pathways regulating both hepatic triglyc-
eride and glucose metabolism in humans.
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